HEPA — Hepion Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $3.11m
- $7.30m
Annual income statement for Hepion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 20.1 | 30.4 | 45.5 | 48.4 | 19.3 |
| Operating Profit | -20.1 | -30.4 | -45.5 | -48.4 | -19.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20.3 | -32.7 | -45.1 | -49.3 | -16.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -20.4 | -32.7 | -42.2 | -48.9 | -13.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -20.4 | -32.7 | -42.2 | -48.9 | -13.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -20.4 | -32.7 | -45.3 | -48.9 | -13.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -42.1 | -9.31 | -11.6 | -11.8 | -107 |